Bandwidth Inc vs Bristol-Myers Squibb Co — how do they compare? Bandwidth Inc trades at $51.38 (market cap $1.66B), while Bristol-Myers Squibb Co trades at $63.92 (market cap $129.94B). The key difference: Bristol-Myers Squibb Co is far larger — about 78.3× Bandwidth Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Bandwidth Inc pays none. Which is the better fit depends on your goals.
| BAND | BMY | |
|---|---|---|
Market Cap | $1.66B | $129.94B |
Sector | Technology | Health |
52-Week High | $78.44 | $65.89 |
52-Week Low | $12.82 | $42.60 |
Enterprise Value | $2.04B | $163.92B |
Dividend Yield | — | 3.96% |
Signals from Pluang's Aura AI — not financial advice
Bandwidth (BAND) trades at $52.30, down 0.78% on the day, with strong technical momentum showing bullish moving averages but overbought RSI signals. The company demonstrated solid Q2 2026 performance with EPS of $0.37 beating estimates and 22% revenue growth, driven by AI-driven communications demand and enterprise wins. Analyst sentiment remains overwhelmingly positive with 75% buy ratings and a $75.25 consensus price target representing 44% upside potential.
The outlook appears favorable with accelerating AI adoption and raised 2026 guidance, though valuation remains elevated at 34x EBITDA. Key risks include execution challenges in scaling AI deployments and competitive pressure in cloud communications. Current profitability metrics show improvement but remain thin, requiring sustained growth to justify premium multiples.
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
Trailing returns across standard periods
Latest headlines on both assets
Bandwidth is a global communications software company. Its CPaaS platform allows enterprises to embed voice, messaging, and 911 emergency services directly into their software applications via robust APIs.
Read more on BAND →Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →